Hematology

After reviewing data from 2 randomized placebo-controlled Phase 3 trials and an open-label extension, the FDA has approved a new option for the treatment of adults with chronic immune thrombocytopenia. ...

After results from a recent trial demonstrated its efficacy, the FDA expanded the indication of a cancer drug to include adult patients with chronic graft versus host disease who do not respond to other...

The US Food and Drug Administration recently approved a new treatment option for patients with hemophilia B.

The US Food and Drug Administration recently approved a new treatment option for patients with hemophilia B.